Xvivo Perfusion Croissance future
Future contrôle des critères 5/6
Xvivo Perfusion devrait augmenter ses bénéfices et son chiffre d'affaires de 26.3% et de 29.4% par an respectivement. Le BPA devrait croître de de 25.9% par an. Le rendement des capitaux propres devrait être 11.4% dans 3 ans.
Informations clés
26.3%
Taux de croissance des bénéfices
25.9%
Taux de croissance du BPA
| Medical Equipment croissance des bénéfices | 36.9% |
| Taux de croissance des recettes | 29.4% |
| Rendement futur des capitaux propres | 11.4% |
| Couverture par les analystes | Good |
| Dernière mise à jour | 22 Nov 2024 |
Mises à jour récentes de la croissance future
Recent updates
Xvivo Perfusion (STO:XVIVO) Is Posting Healthy Earnings, But It Is Not All Good News
Nov 04
Results: Xvivo Perfusion AB (publ) Beat Earnings Expectations And Analysts Now Have New Forecasts
Oct 27With Xvivo Perfusion AB (publ) (STO:XVIVO) It Looks Like You'll Get What You Pay For
Oct 25Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 40% Undervaluation?
Aug 03Xvivo Perfusion AB (publ) (STO:XVIVO) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected
Apr 25There Are Reasons To Feel Uneasy About Xvivo Perfusion's (STO:XVIVO) Returns On Capital
Apr 11Need To Know: Analysts Just Made A Substantial Cut To Their Xvivo Perfusion AB (publ) (STO:XVIVO) Estimates
Feb 05We Think That There Are Issues Underlying Xvivo Perfusion's (STO:XVIVO) Earnings
Feb 01Earnings Beat: Xvivo Perfusion AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Jan 28Returns On Capital At Xvivo Perfusion (STO:XVIVO) Have Stalled
Aug 24Why Xvivo Perfusion AB (publ) (STO:XVIVO) Could Be Worth Watching
Jul 17Do Xvivo Perfusion's (STO:XVIVO) Earnings Warrant Your Attention?
Jun 16Xvivo Perfusion (STO:XVIVO) May Have Issues Allocating Its Capital
Apr 19Are Investors Undervaluing Xvivo Perfusion AB (publ) (STO:XVIVO) By 21%?
Mar 23With EPS Growth And More, Xvivo Perfusion (STO:XVIVO) Makes An Interesting Case
Mar 07When Should You Buy Xvivo Perfusion AB (publ) (STO:XVIVO)?
Feb 13Be Wary Of Xvivo Perfusion (STO:XVIVO) And Its Returns On Capital
Dec 14Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 35% Undervaluation?
Nov 17Xvivo Perfusion (STO:XVIVO) Might Be Having Difficulty Using Its Capital Effectively
Aug 20Statutory Profit Doesn't Reflect How Good Xvivo Perfusion's (STO:XVIVO) Earnings Are
Jul 21Be Wary Of Xvivo Perfusion (STO:XVIVO) And Its Returns On Capital
Mar 30At kr258, Is Xvivo Perfusion AB (publ) (STO:XVIVO) Worth Looking At Closely?
Feb 18A Look At The Fair Value Of Xvivo Perfusion AB (publ) (STO:XVIVO)
Jan 30Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2026 | 1,525 | 302 | 150 | 401 | 5 |
| 12/31/2025 | 1,138 | 175 | -4 | 244 | 6 |
| 12/31/2024 | 825 | 123 | 6 | 178 | 5 |
| 9/30/2024 | 751 | 204 | -118 | 67 | N/A |
| 6/30/2024 | 699 | 121 | -103 | 69 | N/A |
| 3/31/2024 | 643 | 100 | -93 | 60 | N/A |
| 12/31/2023 | 598 | 92 | -98 | 46 | N/A |
| 9/30/2023 | 573 | 24 | -72 | 50 | N/A |
| 6/30/2023 | 524 | 27 | -86 | 42 | N/A |
| 3/31/2023 | 463 | 28 | -108 | 25 | N/A |
| 12/31/2022 | 415 | 18 | -103 | 28 | N/A |
| 9/30/2022 | 370 | 30 | -127 | 6 | N/A |
| 6/30/2022 | 328 | 23 | -138 | -20 | N/A |
| 3/31/2022 | 293 | 7 | -138 | -32 | N/A |
| 12/31/2021 | 258 | 8 | -106 | -12 | N/A |
| 9/30/2021 | 233 | -24 | -116 | -33 | N/A |
| 6/30/2021 | 221 | -37 | -104 | -27 | N/A |
| 3/31/2021 | 192 | -44 | -79 | -11 | N/A |
| 12/31/2020 | 180 | -44 | -77 | -12 | N/A |
| 9/30/2020 | 182 | -26 | -68 | 3 | N/A |
| 6/30/2020 | 194 | -6 | -54 | 20 | N/A |
| 3/31/2020 | 220 | 12 | -49 | 39 | N/A |
| 12/31/2019 | 221 | 5 | -54 | 30 | N/A |
| 9/30/2019 | 217 | 12 | -37 | 34 | N/A |
| 6/30/2019 | 203 | 7 | -42 | 23 | N/A |
| 3/31/2019 | 193 | 9 | -41 | 15 | N/A |
| 12/31/2018 | 188 | 13 | -31 | 24 | N/A |
| 9/30/2018 | 171 | 13 | -21 | 34 | N/A |
| 6/30/2018 | 162 | 13 | N/A | 38 | N/A |
| 3/31/2018 | 153 | 10 | N/A | 33 | N/A |
| 12/31/2017 | 148 | 6 | N/A | 22 | N/A |
| 9/30/2017 | 145 | 0 | N/A | 8 | N/A |
| 6/30/2017 | 145 | 0 | N/A | 6 | N/A |
| 3/31/2017 | 142 | 0 | N/A | 5 | N/A |
| 12/31/2016 | 138 | 2 | N/A | 13 | N/A |
| 9/30/2016 | 132 | 5 | N/A | 22 | N/A |
| 6/30/2016 | 127 | 7 | N/A | 19 | N/A |
| 3/31/2016 | 122 | 6 | N/A | 20 | N/A |
| 12/31/2015 | 120 | 5 | N/A | 9 | N/A |
| 9/30/2015 | 113 | 4 | N/A | -1 | N/A |
| 6/30/2015 | 109 | 4 | N/A | 1 | N/A |
| 3/31/2015 | 98 | 3 | N/A | -7 | N/A |
| 12/31/2014 | 85 | 5 | N/A | -5 | N/A |
| 9/30/2014 | 79 | 6 | N/A | 9 | N/A |
| 6/30/2014 | 74 | 7 | N/A | 3 | N/A |
| 3/31/2014 | 71 | 7 | N/A | 6 | N/A |
| 12/31/2013 | 69 | 8 | N/A | 13 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de XVIVO ( 26.3% par an) est supérieure au taux d'épargne ( 1.2% ).
Bénéfices vs marché: Les bénéfices de XVIVO ( 26.3% par an) devraient croître plus rapidement que le marché Swedish ( 15% par an).
Croissance élevée des bénéfices: Les bénéfices de XVIVO devraient augmenter de manière significative au cours des 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de XVIVO ( 29.4% par an) devrait croître plus rapidement que le marché Swedish ( 0% par an).
Croissance élevée des revenus: Le chiffre d'affaires de XVIVO ( 29.4% par an) devrait croître plus rapidement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de XVIVO devrait être faible dans 3 ans ( 11.4 %).